TaiGen Biopharmaceuticals Holdings Limited

TaiGen Biopharmaceuticals Holdings Limited is a biotechnology company focused on the research, development, and commercialization of novel therapeutics targeting major unmet medical needs. Established in 2001 and headquartered in Taipei, TaiGen addresses serious health challenges through its innovative drug pipeline, which includes both small molecule drugs and advanced biologics. The company’s portfolio targets infectious diseases, cancer, diabetes-related complications, and conditions requiring stem cell transplantation. Notable developments include Nemonoxacin, a non-fluorinated quinolone antibiotic developed for drug-resistant bacterial infections and community-acquired pneumonia, as well as TG-1000 for influenza and Furaprevir for chronic hepatitis C. TaiGen’s products are at various stages of clinical trials, with some already approved or marketed in select regions. Beyond drug development, TaiGen provides pharmaceutical technology consulting and is involved in health food manufacturing and sales. By advancing therapies from discovery to late-stage clinical development, TaiGen Biopharmaceuticals Holdings Limited plays a significant role in Taiwan’s healthcare sector and contributes to global medical innovation.